Showing 3191-3200 of 4063 results for "".
- Atsena Therapeutics Secures FDA Rare Pediatric Disease Designation for XLRS Gene Therapyhttps://modernod.com/news/atsena-therapeutics-secures-fda-rare-pediatric-disease-designation-for-gene-therapy-targeting-x-linked-retinoschisis/2482398/The FDA has granted rare pediatric disease (RPD) designation for Atsena Therapeutics' gene therapy pruduct candidate ATSN-201, which is being examined to treat X-linked retinoschisis (XLRS). XLRS is a rare genetic disorder that leads to vision loss primarily in males.
- Contact Lens Institute Opens Nominations for Second Annual Culture Awardshttps://modernod.com/news/contact-lens-institute-opens-nominations-for-second-annual-culture-awards/2482394/The Contact Lens Institute (CLI) has announced that nominations for the second annual CLI Culture Awards are now open, with submissions being accepted through October 1, 2024. This program aims to recognize eye care professionals who are committed to fostering a positive culture around contact le
- NIH Study Reveals Significant Gaps in Medicaid Coverage for Adult Vision Carehttps://modernod.com/news/nih-study-reveals-significant-gaps-in-medicaid-coverage-for-adult-vision-care/2482392/A recent study funded by the National Institutes of Health (NIH) has uncovered significant disparities in Medicaid coverage for adult vision care across the United States. The study, which analyzed 2022-23 state policies, reveals that millions of Medicaid enrollees lack access to basic vision ser
- LumiThera Announces First CPT Code to Report Photobiomodulation Therapy in Retinal Diseasehttps://modernod.com/news/lumithera-announces-first-cpt-code-to-report-photobiomodulation-therapy-in-retinal-disease/2482389/LumiThera announced a new Category III CPT code, effective January 1, 2025. The code, "Photobiomodulation therapy of retina, single session,” was approved by the AMA’s CPT Editorial Panel at the May 2024 meeting.[1] The LIGHTSITE III clinical trial was a
- Vabysmo Showed Extended Durability, Continued Efficacy and a Consistent Safety Profile in Long-Term DME Studyhttps://modernod.com/news/vabysmo-showed-extended-durability-continued-efficacy-and-a-consistent-safety-profile-in-long-term-dme-study/2482363/At the American Society of Retina Specialists (ASRS) 2024 Annual Meeting in Stockholm, Sweden, Genentech announced new, 4-year data from the RHONE-X extension study. The study met all primary endpoints, showing that Vabysmo (faricimab-svoa) was well tolerated in people with diabetic mac
- Opthea Welcomes International Retina Thought Leaders to Its Medical Advisory Boardhttps://modernod.com/news/opthea-welcomes-international-retina-thought-leaders-to-its-medical-advisory-board/2482361/Opthea announced the formation of its Medical Advisory Board, which will comprise of 10 retina thought leaders from countries around the world, including the US, Argentina, Australia, China, France, Germany, and Israel. Chaired by Arshad M. Khanani, MD, MA, FASRS, Chief Medica
- Claes H. Dohlman, MD, Cornea Research Pioneer and Visionary, Passes Away at 101https://modernod.com/news/claes-h-dohlman-md-cornea-research-pioneer-and-visionary-passes-away-at-101/2482356/Cornea Research Pioneer Claes H. Dohlman, MD, PhD, professor of Ophthalmology, Emeritus, and former Chief and Chair of the Department of Ophthalmology at Mass Eye and Ear and Harvard Medical School (HMS), passed away at the age of 101 on July 14, 2024, Mass Eye and Ear announced on Monday.
- Mount Sinai Ophthalmologists Present New Research at ASRShttps://modernod.com/news/mount-sinai-ophthalmologists-present-new-research-at-asrs/2482355/Ophthalmologists from New York Eye and Ear Infirmary of Mount Sinai in New York City have prepared the following research for the ASRS annual meeting in Stockholm, Sweden, July 17-20. FOUNDERS AWARD WINNER LECTURE Jammi
- iOR Partners Appoints Lance J. Kugler, MD, to the Role of Strategic Advisory Board Chairmanhttps://modernod.com/news/ior-partners-appoints-lance-j-kugler-md-to-the-role-of-strategic-advisory-board-chairman/2482351/Ophthalmic office-based surgery provider IOR Partners announced that Lance J. Kugler, MD, has been named Chairman of the Strategic Advisory Board. Dr. Kugler opened one of the first OBS suites in 2017 and published a study on the safety of office-based lens surgery in The
- Harrow Enters into 340B Prime Vendor Program Contract with Apexus for Iheezohttps://modernod.com/news/harrow-enters-into-340b-prime-vendor-program-contract-with-apexus-for-iheezo/2482349/Harrow announced that as of July 1, 2024, it has entered into an agreement with Apexus to make Iheezo (chloroprocaine hydrochloride ophthalmic gel) 3% and other Harrow products available through its 340B Prime Vendor Program. Iheezo, indicated for ocular anesthesia, is a low-visc